Sugi Predict

Sugi Predict / Compounds / SCHEMBL758457

SCHEMBL758457

SCHEMBL758457

CC(C)(C)OC(=O)N1CCCC(CCBr)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ GLS O94925 2/20 0.50
▸ BACE1 P56817 2/20 0.48
▸ CTSD P07339 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ FPR2 P25090 2/20 0.46
▸ FPR3 P25089 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ ACKR3 P25106 1/20 0.46
▸ NR1H2 P55055 1/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ FEN1 P39748 1/20 0.44
▸ SCN9A Q15858 1/20 0.44
▸ EPHX1 P07099 1/20 0.42
▸ KAT7 O95251 1/20 0.40
▸ KAT8 Q9H7Z6 1/20 0.40
▸ PREP P48147 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7685622 1.00 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7691100 1.00 MEN1 (0.52) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7686514 0.92 GLS (0.51) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7686804 0.92 GLS (0.51) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL6959152 0.92 GLS (0.51) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL3247525 0.91 NR1H2 (0.47) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL14921079 0.91 NR1H2 (0.47) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL7692869 0.89 GLS (0.49) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL1978233 0.88 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS
SCHEMBL376819 0.88 MEN1 (0.54) MEN1ALDH1A1MAPTKMT2AGLS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4263518-B1 NEW QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 — — CN disclosed
CN-111918651-B GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-01-30 — — CN disclosed
US-20230331682-A1 NEW QUINAZOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-10-19 — — US disclosed
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2022-10-27 — — US disclosed
CN-111918651-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2020-11-10 — — CN disclosed
CN-110997671-A Azaindole compounds as histone methyltransferase inhibitors 全球血液疗法股份有限公司 2020-04-10 — — CN disclosed
US-10336727-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2019-07-02 — — US disclosed
CN-101481380-A Thiofuran pyridazine compound, preparation thereof, pharmaceutical composition and uses thereof ZHEJIANG MEDICINE CO LTD (CN) 2009-07-15 — — CN disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 — — WO disclosed
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2007-12-27 — — US disclosed
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2007-12-27 — — US disclosed
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MYRIAD GENETICS, INCORPORATED (US) 2007-12-27 — — US disclosed
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists BRITTON THOMAS CHARLES (US) 2002-01-17 — — US disclosed
US-6255494-B1 SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS ELI LILLY AND COMPANY 2001-07-03 — — US disclosed
US-6245761-B1 NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS ELI LILLY AND COMPANY 2001-06-12 — — US disclosed
EP-0871442-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1998-10-21 — — EP disclosed
WO-1997025041-A1 BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331682-A1 NEW QUINAZOLINONE DERIVATIVES NDUFS3, NQO2, NDUFC1 MEN1 2070/4885ALDH1A1 307/4885MAPT 3063/4885
US-20070299258-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER MCL1, TP53, TUBB3 MEN1 1604/4885ALDH1A1 201/4885MAPT 2528/4885
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists NPY1R, NPY2R, NPY5R MEN1 815/4885ALDH1A1 4251/4885MAPT 3175/4885
US-10336727-B2 Histone demethylase inhibitors KDM1B, KDM5A, KDM5C MEN1 2685/4885ALDH1A1 306/4885MAPT 2573/4885
US-20220340577-A1 GCN2 INHIBITORS AND USES THEREOF EIF2AK4, GCN1, GCGR MEN1 3168/4885ALDH1A1 4414/4885MAPT 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.